SELECT (Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity) is the largest cardiovascular outcome trial of a GLP-1 receptor agonist in adults without diabetes. Results led to the first FDA approval of a weight-management drug for a cardiovascular outcome.
Trial design
SELECT (Lincoff et al., NEJM 2023) enrolled 17,604 adults with BMI ≥27 and established CVD, without diabetes. Randomized to semaglutide 2.4 mg weekly or placebo, on top of standard CV care.
Results
| Endpoint | Semaglutide | Placebo | Effect |
|---|---|---|---|
| MACE (3-point) | 6.5% | 8.0% | 20% relative reduction (HR 0.80, p<0.001) |
| CV death | 2.5% | 3.0% | HR 0.85 |
| Non-fatal MI | 2.7% | 3.7% | HR 0.72 |
| Non-fatal stroke | 1.7% | 1.9% | HR 0.93 |
| Weight at 52 wk | −9.4% | −0.9% | −8.5% difference |
Median follow-up 39.8 months. MACE benefit emerged early (within 6 months) and persisted.
Mechanism beyond weight loss
The CV benefit appears larger than would be predicted from weight loss alone. Proposed mechanisms: direct GLP-1 effects in vascular endothelium and myocardium, reduced systemic inflammation, improved insulin sensitivity, blood pressure reduction.
Regulatory and coverage implications
- March 2024: FDA approved Wegovy for cardiovascular event reduction in adults with BMI ≥27 + established CVD. First weight-management drug ever approved for a CV outcome.
- Medicare: since March 2024, Part D plans may cover Wegovy for its cardiovascular indication; separately, the Medicare GLP-1 Bridge ($50 copay, July 1, 2026 to December 31, 2027) covers Foundayo, Wegovy and the Zepbound KwikPen for eligible Part D enrollees; people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge.
- Commercial plans: increasingly covering Wegovy under PA criteria mirroring SELECT enrollment.
What "established CVD" means
SELECT enrolled patients with any of: prior MI, prior ischemic or hemorrhagic stroke, or symptomatic PAD. Patients with diabetes were excluded.
What we don't yet know
- Primary prevention in obesity without established CVD — not studied.
- Tirzepatide CV outcomes — SURPASS-CVOT found tirzepatide non-inferior to dulaglutide; the Mounjaro label (revised August 2026) added a cardiovascular indication for adults with type 2 diabetes.
- Long-term effects beyond 5 years — no GLP-1 CV trial has reported past 5-year follow-up in obesity without diabetes.
See our detailed cardiovascular conditions page.